Debiopharm and innovation
1
Š Debiopharm Group 2009
Debiopharm Group
Founded in 1979, privately owned, financially independant
300 Employees worldwide with headquarters in Lausanne, Switzerland 42 % scientists (MDs, PhDs, pharmacists)
> 400 international network of experts ‘on call’
Key expertise : Drug Development
. Montreal
2
28.05.2009
Paris .. Lausanne Martigny
© Debiopharm Group 2009
Business Model: Bridging Discovery to Market
Discovery
DEBIOPHARM GROUP
Market
Fully funded drug development & innovation Pharma
Academic institutions Biotech Start up Pharma
sanofi-aventis, Ipsen, Watson, Pfizer and others
Kirin, EPFL, Tulane University, Shanghai Institute (SIMM),Nanocarrier and others
from molecule
3
28.05.2009
Added Value
to drug approval
Š Debiopharm Group 2009
Our products
Decapeptyl ®. and Trelstar ® (USA) Indications: advanced prostate cancer, endometriosis, precocious puberty, uterine fibroids, Paraphilia - Ipsen’s # 1 product - Current licensee sales: 400 million USD
Eloxatin ® awarded 2004 Prix Galien - Indications: 1st line, 2nd line, adjuvant, neoadjuvant metastatic colorectal cancer - sanofi-aventis’ # 6 product - Current licensee sales : 2.3 billion USD 4
28.05.2009
© Debiopharm Group 2009
Poly-Lactide-Glycolide : PLG
Hydrolysis
Lactic acid + Glycolic acid
Degradation time (1 week to 6 months) function of : • Ratio L:G • Mw (Inherant viscosity, i.v.) • Terminal end groups (laurylester, PEG, -COOH)
5
28.05.2009
© Debiopharm Group 2009
Pt loaded Polymeric Nano-Micelles
H2 N
OOC
COO
N H2
H2 N
MeO (CH2CH2O)n CH2CH2CH2 NH C O
ONO2
+
Pt
CH
H N
CH2
OOC Pt
Pt OOC
H2N
NH2
H m
CH2 C
N H2
ONO2
O
ONa
Mean diameter 30 nm
6
28.05.2009
Š Debiopharm Group 2009
Pt loaded Polymeric Nano-Micelles
Total Platinum in plasma in C38 mouse model after IV injection of ND formulations or L-OHP 100000
L-OHP (060016) L-OHP (060048)
ng Pt/ ml
10000
ND-01-01 (060048) ND-01-02 (060016)
1000
ND-01-03 (060016)
100
AUC 0-96h total platinum in tumor
10 0
24
48
72
96
ng Pt/g.h
hours
200000 180000 160000 140000 120000 100000 80000 60000 40000 20000 0 l-OHP
7
28.05.2009
ND-01-01 Š Debiopharm Group 2009
Antitumor Activity assay
In vivo bioluminescent imaging (IVIS Imaging System, Xenogen) HeLa-Luc i.p metastases at day 15 (D-luciferin injected at 150 mg/kg 10 minutes before) B. Saline;
8
28.05.2009
C. oxaliplatin 6 mg/kg;
D. DACHPt micelles 6 mg/kg.
Š Debiopharm Group 2009
Re-design of Drugs
EXAMPLE: synthesis of Debio-025 (Anti-HcV) Immunosuppressive
Antiviral
O
9
28.05.2009
Š Debiopharm Group 2009
Conclusion: Origine de l’innovation
10
Bottom up (production) Curiosité, analyse (comprendre pour innover, améliorer)
Top down (R&D) Association d’idées différentes Expression du besoin Idées de ruptures/passer les barrières Confronter des visions différentes
28.05.2009
© Debiopharm Group 2009
Conditions cadres pour innovation CH
11
28.05.2009
EPFL learning center
Š Debiopharm Group 2009
Conditions cadres valaisannes, il faut rĂŞver!
12
28.05.2009
Š Debiopharm Group 2009